Dublin, March 09, 2018 -- The "Global Gynecology Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Gynecology Partnering 2012-2018: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.
The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report scope
Global Gynecology Partnering 2012 to 2018 includes:
- Trends in Gynecology dealmaking in the biopharma industry since 2012
- Analysis of Gynecology deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Gynecology deal contract documents
- Comprehensive access to over 3500 Gynecology deal records
- The leading Gynecology deals by value since 2012
- Most active Gynecology dealmakers since 2012
The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.
In Global Gynecology Partnering 2012 to 2018, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Gynecology dealmaking
2.1. Introduction
2.2. Gynecology partnering over the years
2.3. Gynecology partnering by deal type
2.4. Gynecology partnering by industry sector
2.5. Gynecology partnering by stage of development
2.6. Gynecology partnering by technology type
2.7. Gynecology partnering by therapeutic indication
Chapter 3 -Financial deal terms for Gynecology partnering
3.1. Introduction
3.2. Disclosed financials terms for Gynecology partnering
3.3. Gynecology partnering headline values
3.4. Gynecology deal upfront payments
3.5. Gynecology deal milestone payments
3.6. Gynecology royalty rates
Chapter 4 - Leading Gynecology deals and dealmakers
4.1. Introduction
4.2. Most active in Gynecology partnering
4.3. List of most active dealmakers in Gynecology
4.4. Top Gynecology deals by value
Chapter 5 - Gynecology contract document directory
5.1. Introduction
5.2. Gynecology partnering deals where contract document available
Chapter 6 - Gynecology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Gynecology therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/3tsflw/global_gynecology?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health


Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Jetstar to Charge for Overhead Cabin Bags From February
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 



